The FDA Has Accepted And Granted Priority Review AstraZeneca's Supplemental New Drug Application For Calquence (Acalabrutinib) For Previously Untreated Mantle Cell Lymphoma, The FDA Action Date Is Anticipated During Q1 Of 2025
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted and granted priority review to AstraZeneca's supplemental new drug application for Calquence (Acalabrutinib) for previously untreated mantle cell lymphoma. The FDA action date is anticipated during Q1 of 2025.
October 03, 2024 | 9:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Calquence has received FDA priority review for use in untreated mantle cell lymphoma, with a decision expected in Q1 2025. This could potentially expand the drug's market and boost revenues.
The FDA's priority review status indicates a potential for significant impact on treatment options, which could lead to increased market share and revenues for AstraZeneca if approved. The anticipation of a decision in Q1 2025 provides a timeline for investors to watch.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90